SSA
KYTX icon

Schonfeld Strategic Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
20,154
-8,718
-30% -$72.6K ﹤0.01% 1775
2025
Q4 		$271K Buy
+28,872
New +$214K ﹤0.01% 1608
2024
Q3 		– Sell
-61,303
Closed -$460K – 2487
2024
Q2 		$460K Buy
+61,303
New +$937K ﹤0.01% 1525

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Schonfeld Strategic Advisors's KYTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Kyverna Therapeutics (KYTX) stake by 30% in Q1 2026, selling an estimated $72.6K and leaving 20,154 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Schonfeld Strategic Advisors first reported a position in KYTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $460K in Q2 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Schonfeld Strategic Advisors held 20,154 shares of Kyverna Therapeutics worth $174K as of Q1 2026.
  • Schonfeld Strategic Advisors sold 8,718 Kyverna Therapeutics shares in Q1 2026, an estimated $72.6K.
  • Kyverna Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1775 holding.
  • Schonfeld Strategic Advisors first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Schonfeld Strategic Advisors's Kyverna Therapeutics position peaked at $460K in Q2 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.